{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:14:11Z","timestamp":1785190451655,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41409-025-02527-z","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T14:29:09Z","timestamp":1739370549000},"page":"529-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-4748","authenticated-orcid":false,"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-1663","authenticated-orcid":false,"given":"Jurjen","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-0708","authenticated-orcid":false,"given":"Lorenzo","family":"Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-8068","authenticated-orcid":false,"given":"Juan","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn","family":"Van Gorkom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-7346","authenticated-orcid":false,"given":"Peter","family":"von dem Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loron","family":"Sandrine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-5581","authenticated-orcid":false,"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-7774","authenticated-orcid":false,"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-3895","authenticated-orcid":false,"given":"Jan","family":"Vydra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-418X","authenticated-orcid":false,"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5908-0792","authenticated-orcid":false,"given":"Simona","family":"Piemontese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2527_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361.","journal-title":"J Clin Oncol"},{"key":"2527_CR2","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"M Aoudjhane","year":"2005","unstructured":"Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey. Leukemia. 2005;19:2304\u201312.","journal-title":"Leukemia"},{"key":"2527_CR3","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.31941","volume":"125","author":"N Santoro","year":"2019","unstructured":"Santoro N, Labopin M, Ciceri F, Van Lint MT, Nasso D, Blaise D, et al. Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. Cancer. 2019;125:1499\u2013506.","journal-title":"Cancer"},{"key":"2527_CR4","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","volume":"27","author":"O Ringd\u00e9n","year":"2009","unstructured":"Ringd\u00e9n O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27:4570\u20137.","journal-title":"J Clin Oncol"},{"key":"2527_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/sj.bmt.1704416","volume":"33","author":"A Bacigalupo","year":"2004","unstructured":"Bacigalupo A. Third EBMT\/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transpl. 2004;33:691\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2527_CR6","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2527_CR7","doi-asserted-by":"crossref","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55:1114\u201325.","DOI":"10.1038\/s41409-020-0803-y"},{"key":"2527_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273\u201383.","journal-title":"J Clin Oncol"},{"key":"2527_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2527_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"2527_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"2527_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med. 1999;18:695\u2013706.","journal-title":"Stat Med"},{"key":"2527_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc B.1972;34:187\u2013220.","journal-title":"J R Stat Soc B."},{"key":"2527_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1177\/0962280216647981","volume":"27","author":"L Biard","year":"2018","unstructured":"Biard L, Labopin M, Chevret S, Resche-Rigon M. Investigating covariate-by-centre interaction in survival data. Stat Methods Med Res. 2018;27:920\u201332.","journal-title":"Stat Methods Med Res"},{"key":"2527_CR15","doi-asserted-by":"publisher","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140. https:\/\/doi.org\/10.1182\/blood.2022016867.","DOI":"10.1182\/blood.2022016867"},{"key":"2527_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","volume":"14","author":"J Sanz","year":"2021","unstructured":"Sanz J, Galimard J-E, Labopin M, Afanasyev B, Sergeevich MI, Angelucci E, et al. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. J Hematol Oncol. 2021;14:84.","journal-title":"J Hematol Oncol"},{"key":"2527_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","volume":"13","author":"J Sanz","year":"2020","unstructured":"Sanz J, Galimard J-E, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46.","journal-title":"J Hematol Oncol"},{"key":"2527_CR18","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/s41409-020-0921-6","volume":"55","author":"J Montoro","year":"2020","unstructured":"Montoro J, Pi\u00f1ana JL, Hern\u00e1ndez-Boluda JC, Hernani R, Lorenzo I, P\u00e9rez A, et al. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transpl. 2020;55:2147\u201359.","journal-title":"Bone Marrow Transpl"},{"key":"2527_CR19","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41409-022-01725-3","volume":"57","author":"L Lazzari","year":"2022","unstructured":"Lazzari L, Balaguer-Rosell\u00f3 A, Montoro J, Greco R, Hernani R, Lupo-Stanghellini MT, et al. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transpl. 2022;57:1389\u201398.","journal-title":"Bone Marrow Transpl"},{"key":"2527_CR20","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/bloodadvances.2023012133","volume":"8","author":"J Sanz","year":"2024","unstructured":"Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, et al. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. Blood Adv. 2024;8:2332\u201341.","journal-title":"Blood Adv"},{"key":"2527_CR21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.leu.2404037","volume":"20","author":"A Shimoni","year":"2006","unstructured":"Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20:322\u20138.","journal-title":"Leukemia"},{"key":"2527_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ajh.24632","volume":"92","author":"S Gaballa","year":"2017","unstructured":"Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, et al. Relapse risk and survival in patients with FLT3 acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017;92:331.","journal-title":"Am J Hematol"},{"key":"2527_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2991\/chi.d.190310.001","volume":"1","author":"A Bazarbachi","year":"2019","unstructured":"Bazarbachi A, Labopin M, Battipaglia G, Djabali A, Forcade E, Arcese W, et al. Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia: in vivo T-cell depletion and posttransplant sorafenib maintenance improve survival. a retrospective acute leukemia working party-European Society for Blood and Marrow Transplant Study. Clin Hematol Int. 2019;1:58\u201374.","journal-title":"Clin Hematol Int"},{"key":"2527_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.bbmt.2018.09.012","volume":"25","author":"MM Solh","year":"2019","unstructured":"Solh MM, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A. The dilemma of conditioning intensity: when does myeloablative conditioning improve outcomes for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2019;25:606\u201312.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2527_CR25","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020;105:1507\u201316.","journal-title":"Haematologica"},{"key":"2527_CR26","doi-asserted-by":"publisher","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for acute myeloid leukemia with internal tandem duplication mutation of FLT3. 2024. https:\/\/doi.org\/10.1200\/JCO.23.02474.","DOI":"10.1200\/JCO.23.02474"},{"key":"2527_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/ejh.13692","volume":"107","author":"JD Griffin","year":"2021","unstructured":"Griffin JD, Song Y, Yang H, Freimark J, Shah MV. Post\u2010transplant maintenance therapy in patients with FLT3\u2010mutated acute myeloid leukemia: Real\u2010world treatment patterns and outcomes. Eur J Haematol. 2021;107:553.","journal-title":"Eur J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02527-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02527-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02527-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T05:11:40Z","timestamp":1743829900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02527-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2527"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02527-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The scientific board of the ALWP of EBMT approved this study. All patients gave written informed consent for the use of their data. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for individual patient data. This is a pooled analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}